Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytotect CP for CMV Prophylaxis in Acute GVHD
NCT05370976Phase 2Terminated
- Sponsor
- CHU de Lille
- Start
- Sep 2022
- Primary completion
- Aug 2023
- Modality
- IgG Antibodies, Antibody Conjugates, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of human cytomegalovirus immune globulin in cytomegalovirus infection (CMV), sponsored by CHU de Lille. Started Sep 2022; status: terminated.
02
Drugs
human cytomegalovirus immune globulin
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT05370976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05370976.